甲磺酸阿帕替尼治疗晚期肺癌不良反应的护理观察
Nursing observation of adverse reactions of advanced lung cancer treated with Apa imatinib mesylate
俞智敏 1陈美华 1张沂平 1叶小红1
作者信息
- 1. 浙江省肿瘤医院 112病区,浙江 杭州 310022
- 折叠
摘要
目的 研究60例晚期非小细胞肺癌患者在进行甲磺酸阿帕替尼治疗后的不良反应,并制定针对这些不良反应的护理方法 .方法 选取2015年9月～2016年9月在浙江省肿瘤医院胸部肿瘤内科就诊并且接受治疗的非小细胞肺癌患者为研究对象,给予甲磺酸阿帕替尼片治疗,观察患者治疗过程中出现的不良反应.结果 共有45例患者发生不良反应,不良反应发生率为75.00％.其中29例子患者发生皮疹,24例患者发生高血压,30例患者发生腹泻,21例患者出现恶心呕吐,5例患者出现蛋白尿,口腔黏膜炎7例,其他肝功能异常、血小板下降、咯血、乏力各出现2例.对各项不良反应进行针对性护理.结论 晚期非小细胞肺癌患者用甲磺酸阿帕替尼进行治疗后出现不良反应,通过护理干预可以提高患者的生活质量.
Abstract
Objective Study on 60 cases of advanced non-small cell lung cancer patients in the Apa imatinib mesylateadverse reactions after treatment , and to develop nursing methods for these adverse reactions. Methods Non-small cell lung cancer patients who were treated in our hospital from September 2015 to September 2016 were treated with Apa imatinib mesylate and observed the adverse reactions during the course of treatment. Results Adverse reactions occurred in 45 patients, and the incidence of adverse reactions was 75.00％.29 cases of patients with skin rash, 24 cases occurred in patients with hypertension, 30 cases of patients with diarrhea, nausea and vomiting occurred in 21 patients, 5 cases occurred in patients with proteinuria, 7 cases of patients with oral mucositis.Conclusion Non-small cell lung cancer patients had adverse reactions after treatment with Apa imatinib mesylate and nursing intervention can improve the quality of life of patients.
关键词
甲磺酸阿帕替尼/晚期非小细胞肺癌/不良反应Key words
Apa imatinib mesylate/advanced non-small cell lung cancer patients/adverse reactions引用本文复制引用
出版年
2017
NETL
NSTL
维普
万方数据